There are many different ways for venture firms or incubators with the VITAL program. Bring a health care solution to VITAL for testing or sign up for updates on new tests. You can be the first to know when we’ve gathered the right data to support innovation. Contact us to start the conversation.
Discuss the emerging companies we should be aware of
Fast-track solutions testing
Gain insights on how Highmark and other plans and providers evaluate technologies for adoption and coverage
Collaborate on the advancement of care in critical disease states
Landscape opportunities for new products and technologies
Understand the Highmark organization better
Learn Highmark’s mission, vision, and key objectives
Develop relationships with key individuals in the Highmark enterprise, Highmark health plan, and AHN provider system
Tell us about your product or idea. Submit a summary of your project via email, including a problem description, value proposition, proposed solution, timeline, & budget.
Companies accepted into the VITAL process will work closely with us to design the test process, while VITAL performs arigorous opportunity assessment.
VITAL orchestrates testing and delivers comprehensive clinical, cost, & experience data.
Companies accepted into the VITAL process will work closely with us to design the test process, while VITAL performs a rigorous opportunity assessment.
“Torax Medical and physician thought leaders have collaborated … building a strong scientific foundation of evidence to support the safety and efficacy of the LINX procedure. GERD patients who do not respond to medical therapies can create a tremendous cost burden on a health care system and are often at higher risks for complications resulting from not fully treating their disease.”
Todd Berg President and CEO of Torax Medical
“We are very excited to see such lasting results from a 1-month, drug-free treatment that can dramatically improve the quality of life for our patients and reduce total medical costs. It was also very promising to see high therapist and patient satisfaction and 85 percent patient adherence, confirming that using Freespira® as a first line treatment for panic disorder and panic attacks makes good sense clinically and financially.”
Anthony P. Mannarino PhD, Professor and Vice Chair, Department of Psychiatry, Allegheny General Hospital
“In the beginning, when I heard about HeartFlow®, I wanted to talk to my division chief, Dr. Srinivas Murali, about exploring it. But then I heard that Highmark Health and VITAL were already talking to HeartFlow®, which is a company from California. They needed a physician champion to put HeartFlow® to the test, and I expressed interest.”
Moneal Shah Co-director of Cardiovascular MRI, Allegheny Health Network
